Merck Heart, Kidney Drug Fails Late-Stage Clinical Trial
By wchung | 24 Apr, 2026
Merck and Co. said Friday its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.
The company said rolofylline did not reach its primary or secondary goals in the late-stage trial. Based on the results, Merck said it no longer plans to ask the Food and Drug Administration to approve the drug candidate this year.
The trial also showed that 30 mg of rolofylline did not reduce the risk of death or hospitalization due to heart or kidney problems 60 days after treatment, and that it did not reduce kidney impairment.
Merck is still analyzing study data from the study, which is called PROTECT, and it will present full results from the 2,033-patient trial at a medical conference later this year.
In morning trading, Merck shares fell 64 cents, or 2.4 percent, to $25.94.
6/5/2009 10:04 AM WHITEHOUSE STATION, N.J. (AP)
Recent Articles
- Special Forces Sergeant Charged with Making $400,000 on Maduro Removal Bet
- Small Modular Reactor Startup X-Energy Raises over $1 Billion in IPO
- Cisco's Vijoy Pandey Shows Chip that Links Quantum Computers of Different Types
- Gideon Yu is Silicon Valley’s Quietest Deal Closer
- Cannabis Shares Retreat from Rally on Narrow Scope of Rescheduling
- I Regret Having Taken AAPI Heritage Month for Granted
- White House Accuses China of Industrial-Scale Distilling of AI Models
- Vox Momenti: From India with Ambition
- AI Turns Engineers and Project Managers into 'Builders'
- US Farmers Bet on Peas and Lentils on GLP-1-Related Protein Maxxing Trend